Início/MRK

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze MRK in workspace
MRKNYSE/health care

Merck & Co., Inc.

$124.03Up+0,49 (+0,40%)
Research reviewed: 12 de jul. de 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Merck & Co., Inc. operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
123,58
Haut
124,74
Bas
122,44
Capitalisation
306,33 Md
Ratio C/B
34.94
Plus haut sur 52 semaines
--
Dividende
2.750%
Dividende trimestriel
--

3-month price context

O gráfico mostra a tendência recente de 3 meses para ajudar usuários a entender a estrutura de curto prazo antes de abrir o workspace completo de pesquisa.

Investment thesis

Base case
Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. The base case remains conditional on keytruda concentration staying manageable.
Bull case
Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.
Bear case
Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.
Thesis invalidation
Reassess the thesis if merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks.

Key catalysts

  • Oncology franchise growth

    Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses.

  • New product contributions

    Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products.

  • Late-stage pipeline readouts

    A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Principal risks

  • Keytruda concentration

    Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks.

  • Vaccine demand pressure

    Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches.

  • Business-development charges

    Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.

Latest earnings research

2026 Q1

For the quarter ended March 31, 2026, Merck reported sales growth supported by oncology, animal health, and newer launches; acquisition charges produced a quarterly loss, while management increased its full-year sales and non-GAAP EPS outlook ranges.

Valuation interpretation

  • A durable valuation case requires newer products and late-stage assets to reduce dependence on Keytruda before its loss of exclusivity.
  • Pipeline breadth supports strategic optionality, but acquisition spending and uncertain clinical conversion justify a disciplined execution discount.

Peer research

JNJLLYNVO

Recent news

24/7 Wall St. · il y a 8 heures

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Trefis · il y a 8 heures

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Zacks · il y a 11 heures

FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

Trefis · il y a 13 heures

How Does LLY Stock Reach $2,100?

Simply Wall St. · il y a 13 heures

Merck (MRK) Stock Looks Like A Bargain At This Price

Stocktwits · il y a 23 heures

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears

Data and research sources

Research updated: 12 de jul. de 2026, 00:00 UTC
3 verified sources
Merck Announces First-Quarter 2026 Financial ResultsMerck & Co., Inc. · earningsVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 30/04/2026, 00:00:00

Open original source
Merck Investor RelationsMerck & Co., Inc. · companyVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source
Merck Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source

Continue in the research workspace

Keep MRK in context, run a multi-agent analysis, and monitor thesis changes.

Analyze MRK free

Conheça todo o sistema de análise

Cada etapa tem uma função clara e deixa um resultado auditável.

Metodologia de análiseLer relatórios de mercadoExplorar ações

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista Fundamentalista

Analista Fundamentalista se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista de Notícias

Analista de Notícias se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Gestor de Risco

Gestor de Risco se especializa na etapa de Monitorar dentro de Risco e monitoramento e organiza o contexto para os próximos papéis.